Abstract
Ten patients with transitional cell carcinoma (TCC) of the bladder received 3–6 mCi of HMFG1 monoclonal antibody (MAb) intravesically. The antibody was labeled with Tc-99m using the 2-Iminothiolane method. All patients underwent transurethral resection of the bladder tumor within 12–20 h following intravesical administration of99m-Tc-HMFG1. The presence of the radiolabeled MAb in the circulation was studied by measuring the radioactivity in the serum for a period up to 20 h. Three of 10 patients underwent immunoscintigraphy (SPECT) 2–3 h postadministration and cancerous areas could be easily localized. Biopsies were taken from the tumor sites as well as from normal bladder mucosa. Absolute uptake of the administered MAb expressed as percent administered dose/kg of tissue could be evaluated only in eight patients. Multiple specimen taken from various tumor sites in every patient gave a wide range of uptake values ranging from 0 to 9.29% adm. dose/kg, whereas normal tissue uptake values ranged from 0 to 1.63, respectively.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Richie, J. P. (1989) inCancer Principles and Practice of Oncology. (de Vita, V., Hellman, S., Rosenberg, S. A., eds.), Lippincott, Philadelphia, pp. 1008–1022.
Pocock, R. D., Ponder, B. A. J., and O'Sullivan, J. P. (1982)Br. J. Urol. 54, 711–715.
Taylor-Papadimitriou, J., Peterson, J. A., Arklie, J., Burchell, J., Ceriani, R. C., and Bodmer, W. F. (1981)Int. J. Cancer 28, 17–24.
Anagnostaki, E., Skarlos, D., Tamvakis, N., Psaropoulou, P., Blana, E., Bamias, A., et al. (1990)Br. J. Cancer 62(Suppl.), 52–56.
Conn, I. G., Crocker, J., Gutage, L. A., and Wallace, D. M. A. (1988)J. Clin. Pathol. 41, 1191–1195.
Bamias, A., Keane, P., Krausz, T., Williams G., and Epenetos, A. A. (1991)Cancer Res. 54, 724–728.
Zorzos, J., Pozatzidou, P., Pectasides, D., Bamias, A., Sivolapenko, G., Tsalta, K., et al. (1993) InMonoclonal Antibodies 2 (Epenetos, A., ed.), Chapman and Hall, London, pp. 513–517.
Hnatowich, D. J., Chivol, M., and Siebecker, D. A. (1988)J. Nucl. Med. 29, 1428–1434.
Esteban, J. M., Schlom, J., and Ganson, O. A. (1987)J. Nucl. Med. 28, 861–870.
Russell, P. J., Planley, J., and Raghavan, D. (1993)Br. J. Urol. 71, 121–129.
Goedemans, Wth., Panen, K. J., and Ensing, G. (1989)Proceedings of the Third International Symposium on Technetium in Chemistry and Nuclear Medicine, Raven, New York, pp. 595–603.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Malamitsi, J., Zorzos, J., Varvarigou, A.D. et al. Immunotargeting of urothelial cell carcinoma with intravesically administered Tc-99m labeled HMFG1 monoclonal antibody. Cell Biophysics 24, 75–81 (1994). https://doi.org/10.1007/BF02789217
Issue Date:
DOI: https://doi.org/10.1007/BF02789217